27 filings
8-K
HRTX
Heron Therapeutics Inc
20 Dec 19
Entry into a Material Definitive Agreement
4:06pm
8-K
HRTX
Heron Therapeutics Inc
16 Dec 19
Regulation FD Disclosure
4:15pm
8-K
HRTX
Heron Therapeutics Inc
3 Dec 19
Health Canada Grants Priority Review Status for Heron Therapeutics’ New Drug Submission for HTX-011 for Management of Postoperative Pain
7:41am
8-K
HRTX
Heron Therapeutics Inc
12 Nov 19
Results of Operations and Financial Condition
8:40am
8-K
HRTX
Heron Therapeutics Inc
28 Oct 19
Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain
8:41am
8-K
uat q377e3
22 Oct 19
Other Events
8:42am
8-K
edj40kvp 102d
8 Oct 19
Entry into a Material Definitive Agreement
4:01pm
8-K
mg8lrfd9 pirr4
2 Oct 19
Heron Announces Positive Topline Results from Phase 3b Clinical Study of HTX-011 in Total Knee Arthroplasty
7:57am
8-K
mdhovf1to8
1 Oct 19
Heron Therapeutics Appoints Kimberly Manhard to Board of Directors
4:25pm
8-K
8fj6q
1 Oct 19
Heron Therapeutics Appoints Stephen Davis to Board of Directors
4:16pm
8-K
5q95mjfqlf mv5huif96
1 Oct 19
Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain
8:42am
8-K
iu8o8iyalihj2wjh2
20 Aug 19
Heron Therapeutics Announces Publication of Results from EPOCH 2, a Phase 3 Study of HTX-011 in Patients Undergoing Hernia Repair Surgery
8:35am
8-K
1oobkkd m64
5 Aug 19
Results of Operations and Financial Condition
8:40am
8-K
yg1ha98b3ce dlfbhn
17 Jul 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:30am
8-K
kfa8k 509
19 Jun 19
Submission of Matters to a Vote of Security Holders
4:05pm
8-K
dmnlt8um4a3
21 May 19
Heron Therapeutics Announces Publication of Results from Phase 3 EPOCH 1 Study ofHTX-011 in Patients Undergoing Bunionectomy
9:15am
8-K
v04lmtup 71kb3dtz
14 May 19
Heron Therapeutics Presents New Results from Real-world Study Showing
8:35am
8-K
1hsjn0nn ucf
9 May 19
Results of Operations and Financial Condition
8:35am
8-K
nxd84l11220eg
1 May 19
Heron Therapeutics Receives Complete Response Letter FORHTX-011 for the Management of Postoperative Pain
8:06am
8-K
ls9536tzg q2mqeg
1 Apr 19
Heron Announces European Medicines Agency Validation of Marketing Authorisation
8:35am